By admin | Published:
April 4, 2011
April 4, 2011
Norbert Vey
ROME—It is not acceptable to deny patients with acute myeloid leukaemia the most effective treatments on grounds of age alone, according to Norbert Vey, Professor of Haematology at the Universitée de la Méditerrannée, in Marseille and Head of the Leukaemia/MDS Programme at the Institut Paoli Calmettes. He talks with ecancer radio about the scope for improving treatment for elderly patients who have AML.
Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.
Also posted in eCancer Radio |
By admin | Published:
April 4, 2011
April 4, 2011
Reinhard Stauder
ROME—Clinicians will need increasingly to specialise in geriatric oncology to tackle the growing un-met need for appropriate treatment in elderly patients with blood cancers, according to a leading European expert talking at the Rome conference on Blood Cancer in the Elderly. Professor Reinhard Stauder of Innsbruck University tells ecancer radio about the steps he and his colleagues are taking to ensure appropriate therapy for older cancer patients.
Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.
Also posted in eCancer Radio |
By admin | Published:
April 4, 2011
April 4, 2011
Antonio Cherubini
ROME—Co-operation between geriatricians and cancer doctors was being urged at the Rome conference on Blood Cancer In The Elderly by Antonio Cherubini, Associate Professor of Geriatrics at the University of Perugia in Italy. He discusses with ecancer radio his reasons for favouring multi-disciplinary care to achieve individualised effective management.
Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.
Also posted in eCancer Radio |
By admin | Published:
April 2, 2011
April 2, 2011
Richard Sullivan
ROME—Cancer doctors need to face up to the challenge of the global population time bomb of elderly patients with cancer, according to Richard Sullivan, Director of International Affairs at Kings Health Partners Integrated Cancer Centre, based in Guys Hospital, London. He told the Rome conference on Blood Cancer in the Elderly that many older patients with cancer are fit enough to receive the most effective treatments, so better therapy outcomes can be achieved than is often expected. He explains to ecancer radio what needs to be done to face up to this challenge.
Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.
Also posted in eCancer Radio |
By admin | Published:
April 2, 2011
April 2, 2011
Michele Cavo
ROME—Age should be no barrier to the use of novel agents for treating elderly patients with multiple myeloma, according to Michele Cavo, Associate Professor of Haematology at the University School of Medicine, Bologna, Italy, who addressed the European Expert Forum on Blood Cancer In The Elderly in Rome (19-20 March 2011). He tells eancer radio about the clinical decision-making processes needed to achieve better treatment and longer remissions among elderly patients, and explains why each patient should have therapy planned on an individual basis rather than according to chronological age.
Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.
Also posted in eCancer Radio |
By admin | Published:
March 14, 2011
March 14, 2011
Matti Aapro
GENEVA—In advance of the European Expert Forum on Blood Cancer in the Elderly — being held in Rome — there has been a call for action that doctors should avoid denying older patients cancer therapies on the basis of age alone. Dr Matti Aapro — Executive Director of the International Society for Geriatric Oncology and Dean of the Multidisciplinary Oncology Institute in Genolier, Switzerland — talks with eCancer Radio about the difference between chronological and biological age, and highlights some of the practical messages for cancer doctors attending the Rome conference.
Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.
Also posted in eCancer Radio |
By admin | Published:
January 6, 2011
January 6, 2011
George Canellos
ORLANDO—The immunotoxin brentuximab vedotin (SGN 35) has shown efficacy in relapsed and refractory Hodgkin’s Disease in a study from California reported at the American Society of Hematology annual meeting in Orlando. The same agent has also been found to be active against anaplastic large T-cell lymphoma in a study presented at the ASH conference by a group from Seattle. eCancer Radio’s Haematology Editor George Canellos from the Dana-Farber Cancer Institue and Harvard University discusses the clinical promise of these findings for advancing further response rates and “permanent remissions” in Hodgkin’s Disease.
ASH TELEVISION NEWS REPORTS:
For full coverage of the American Society of Hematology’s 2010 Orlando meeting, visit www.eCancerMedicalScience.com for eCancerTV
Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.
Also posted in eCancer Radio |
By admin | Published:
December 11, 2010
December 11, 2010
George Canellos
ORLANDO—In new research the Stanford V chemotherapy regimen for Hodgkin’s Disease was inferior to ABVD because it required “obligate radiotherapy” — according to George Canellos of the Dana-Farber Cancer Institute in Boston — who gives eCancerRadio his opinion of two papers presented at the American Society of Hematology annual meeting (December 3-7, 2010) held in Orlando: one from California comparing the two regimens in patients with stage I/II bulky mediastinal Hodgkin Lymphoma; the second from Illinois in which the same comparison was made in patients who had locally extensive and advanced stage disease.
ASH TELEVISION NEWS REPORTS:
For full coverage of the American Society of Hematology’s 2010 Orlando meeting, visit www.eCancerMedicalScience.com for eCancerTV
Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.
Also posted in eCancer Radio |
By admin | Published:
December 11, 2010
December 11, 2010
George Canellos
ORLANDO—The immunotoxin brentuximab vedotin (SGN 35) has shown efficacy in relapsed and refractory Hodgkin’s Disease in a study from California reported at the American Society of Hematology annual meeting in Orlando. The same agent has also been found to be active against anaplastic large T-cell lymphoma in a study presented at the ASH conference by a group from Seattle. eCancer Radio’s Haematology Editor George Canellos from the Dana-Farber Cancer Institue and Harvard University discusses the clinical promise of these findings for advancing further response rates and “permanent remissions” in Hodgkin’s Disease.
ASH TELEVISION NEWS REPORTS:
For full coverage of the American Society of Hematology’s 2010 Orlando meeting, visit www.eCancerMedicalScience.com for eCancerTV
Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.
Also posted in eCancer Radio |
By admin | Published:
December 11, 2010
December 11, 2010
Philip McCarthy
ORLANDO—Lenalidomide maintenance therapy extended times to disease progression among patients whose multiple myeloma had been treated with autologous stem cell transplantation in a phase III study reported at the American Society of Hematology annual meeting (December 3-7, 2010) in Orlando. Philip McCarthy, Director of the Blood and Marrow Transplant Program at Roswell Park Cancer Institute in Buffalo, New York, discusses the clinical implications of his group’s findings with eCancer Radio.
ASH TELEVISION NEWS REPORTS:
For full coverage of the American Society of Hematology’s 2010 Orlando meeting, visit www.eCancerMedicalScience.com for eCancerTV
Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.
Also posted in eCancer Radio |
By admin | Published:
December 11, 2010
December 11, 2010
George Canellos
ORLANDO—Primary mediastinal large B cell lymphoma responded excellently to a dose-dense schedule of R-CHOP immuno-chemotherapy followed by ICE chemotherapy — without the need for radiotherapy — in a study from New York reported at the American Society of Hematology annual meeting in Orlando. eCancer Radio’s Hematology Editor, George Canellos, of the Dana-Farber Cancer Institute in Boston discusses the importance of these findings.
ASH TELEVISION NEWS REPORTS:
For full coverage of the American Society of Hematology’s 2010 Orlando meeting, visit www.eCancerMedicalScience.com for eCancerTV
Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.
Also posted in eCancer Radio |
By admin | Published:
June 28, 2010
June 28, 2010
Evangelos Terpos, University of Athens
Big improvements in survival among patients with multiple myeloma were reported at the European Hematology Association annual congress in Barcelona by Greek researchers looking at the past decade of therapy with the novel agents: thalidomide, lenalidomide and bortezomib in the “real world” setting. Professor Evangelos Terpos from the University of Athens discusses his groups findings on bone metabolism under novel agent therapy and assesses the impact of these drugs on survival among patients in Greece.
Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.